AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

MESOBLAST LTD

2.110

-0.080-3.65%

Volume:3.28M

Turnover:6.89M

Market Cap:2.72B

PE:-19.74

High:2.170

Open:2.170

Low:2.080

Close:2.190

52wk High:3.310

52wk Low:1.515

Shares:1.29B

Float Shares:786.49M

Volume Ratio:0.91

T/O Rate:0.42%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.107

EPS(LYR):-0.123

ROE:-18.22%

ROA:-6.16%

PB:3.26

PE(LYR):-17.18

Loading ...

Overview Company News Filings

Mesoblast Appoints Philip Facchina as Chair and Lyn Cobley as Audit Chair

Press Release: Mesoblast Announces Changes to Board of Directors' Leadership Roles

Mesoblast Ltd - Philip Facchina Appointed as Non-Executive Chair

THOMSON REUTERS

Mesoblast Ltd - Jane Bell Retires as Chair

THOMSON REUTERS

Mesoblast Ltd-Mesoblast Announces Changes to Board of Director Roles

THOMSON REUTERS

Mesoblast Ltd Files for Offering of Upto $250 Mln Ads Representing Ordinary Shares - SEC Filing

THOMSON REUTERS

Mesoblast to Release 10.2 Million Shares From Voluntary Escrow

MT Newswires Live

Press Release: Mesoblast Retires Senior Debt with Non-Dilutive, Lower Cost, Five-Year Credit Line

Mesoblast Repays Existing Senior Loans From Shareholder's New Five-Year Facility; Shares Rise 3%

MT Newswires Live

ASX Biggest Losers

MT Newswires Live

Has Mesoblast’s Surging Share Price Left Its Future Growth Prospects Underappreciated?

Simply Wall St.

Aspire Announces Major Australia, EU and US Regulatory Milestones, Marking a New Chapter in Its Global Expansion

Mesoblast Says Drug Candidate for Treatment of Severe Acute Graft Versus Host Disease Shows Superior Outcomes Than Ruxolitinib

MT Newswires Live

Mesoblast Study Finds Remestemcel-L Outperforms Ruxolitinib in Treating Steroid-Refractory aGvHD

Independent Study Presented at American Society of Hematology (Ash) Annual Meeting Concludes Remestemcel-L Superior to Ruxolitinib in Clinical Outcomes as Treatment for SR-Agvhd

THOMSON REUTERS

Is Mesoblast (ASX:MSB) Using High-Profile Conferences To Recast Its Core Investment Narrative?

Simply Wall St.

Mesoblast (ASX:MSB) Valuation Check as Investors Eye Piper Sandler Healthcare Conference Update

Simply Wall St.

Matrixport Appoints Dominik Oggenfuss as Chief Executive Officer of Matrixport Asset Management AG

Mesoblast Participation at Piper Sandler Conference

THOMSON REUTERS

Mesoblast (ASX:MSB) Is Up 17.3% After Lifting Revenue Guidance and Announcing NIH Trial Collaboration Has The Bull Case Changed?

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/MSB.AU/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MSB.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"MSB.AU\",,,,,undefined,":{"symbol":"MSB.AU","market":"AU","secType":"STK","nameCN":"MESOBLAST LTD","latestPrice":2.11,"timestamp":1774588320000,"preClose":2.19,"halted":0,"volume":3276490,"delay":0,"changeRate":-0.036529680365296836,"nameEN":"MESOBLAST LTD","floatShares":786490638,"shares":1290302187,"eps":-0.10687726942628903,"marketStatus":"Market Closed","change":-0.08,"latestTime":"03-27 16:12:00 AEDT","open":2.17,"high":2.17,"low":2.08,"amount":6893585,"amplitude":0.041096,"askPrice":2.12,"askSize":15347,"bidPrice":2.09,"bidSize":73368,"shortable":3,"etf":0,"ttmEps":-0.10687726942628903,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1774825200000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":2.19,"openAndCloseTimeList":[[1774566000000,1774587600000]],"volumeRatio":0.9114152317141351,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"MSB.AU","preClose":2.19,"auctionPrice":2.11,"auctionVolume":709695,"auction":3,"marketStatus":"盘后竞价","timestamp":1774588215608}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"MSB.AU\",,,,,undefined,":{"symbol":"MSB.AU","floatShares":786490638,"roa":"-6.16%","roe":"-18.22%","lyrEps":-0.122831,"volumeRatio":0.9114152317141351,"shares":1290302187,"dividePrice":0,"high":2.17,"amplitude":0.041096,"preClose":2.19,"low":2.08,"week52Low":1.515,"pbRate":"3.26","psRate":"28.67","week52High":3.31,"institutionHeld":0,"latestPrice":2.11,"committee":0.654016,"eps":-0.10687726942628903,"divideRate":0,"volume":3276490,"delay":0,"ttmEps":-0.10687726942628903,"open":2.17,"prevYearClose":2.72,"prevWeekClose":2.06,"prevMonthClose":2.24,"prevQuarterClose":2.72,"fiveDayClose":2.06,"twentyDayClose":2.24,"sixtyDayClose":2.72,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MSB.AU\",params:#limit:5,,,undefined,":[{"date":"2025-02-26","symbol":"MSB.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740524400000,"name":null,"time":"","dateTimestamp":1740488400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MSB.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MSB.AU\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2600034371","title":"Mesoblast Appoints Philip Facchina as Chair and Lyn Cobley as Audit Chair","url":"https://stock-news.laohu8.com/highlight/detail?id=2600034371","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600034371?lang=en_us&edition=fundamental","pubTime":"2026-01-02 07:02","pubTimestamp":1767308540,"startTime":"0","endTime":"0","summary":"Mesoblast Limited has announced changes to its Board of Directors. Philip Facchina has been appointed as non-executive Chair, while Lyn Cobley will serve as Chair of the Audit and Risk Committee. Jane Bell will step down as Chair but remain on the board as a non-executive director. William Burns continues as Vice-Chair and Chair of the Nomination and Remuneration Committee.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mesoblast Limited published the original content used to generate this news brief via GlobeNewswire  on January 01, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260101:nNDLbndDRh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","IE00B64PRP62.GBP","LU2210149790.SGD","LU2095319765.USD","IE00B3QW5Z07.USD","LU2210150020.SGD","BK4588","IE00BKPKM429.USD","NDAQ","IE00BGHQF748.EUR","BK7067","MSB.AU","SG9999014039.USD","BK4112","BK7508","BK4585","SG9999014005.SGD","SG9999014013.SGD","LU0314104364.USD","BK7501"],"gpt_icon":0},{"id":"2600034377","title":"Press Release: Mesoblast Announces Changes to Board of Directors' Leadership Roles","url":"https://stock-news.laohu8.com/highlight/detail?id=2600034377","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600034377?lang=en_us&edition=fundamental","pubTime":"2026-01-02 07:02","pubTimestamp":1767308520,"startTime":"0","endTime":"0","summary":"NEW YORK, Jan. 01, 2026  -- Mesoblast Limited , global leader in allogeneic cellular medicines for inflammatory diseases, today announced that as foreshadowed at the recent Annual General Meeting the Board will undertake a number of changes in line with the Company's evolution to a revenue-generating commercial company.Having presided during the most transformational period for the company with its first U.S. Food & Drug Administration  approval and successful product commercialization, Ms Jane Bell will retire from her role as Chair and will remain on the Board as a non-executive director. The Board has unanimously appointed Mr Philip Facchina to the role of non-executive Chair and Ms Lyn Cobley as Chair of the Audit and Risk Committee. Mr William Burns remains as Mesoblast Vice-Chair and Chair of the Nomination and Remuneration Committee.Mr Facchina joined the Mesoblast board in March 2021 and has over forty years of experience in corporate strategy, finance, and business development","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","R","BK4022","MSC","MSB","MSB.AU","MESO","BK4150","BK4006","BK4139","BK7508","BK4575","BK7501","BK7067"],"gpt_icon":0},{"id":"2600310560","title":"Mesoblast Ltd - Philip Facchina Appointed as Non-Executive Chair","url":"https://stock-news.laohu8.com/highlight/detail?id=2600310560","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600310560?lang=en_us&edition=fundamental","pubTime":"2026-01-02 06:38","pubTimestamp":1767307110,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260101:nTUE9FP4WP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MSB.AU","MESO","BK7508","BK4139","BK7501","BK7067"],"gpt_icon":0},{"id":"2600031055","title":"Mesoblast Ltd - Jane Bell Retires as Chair","url":"https://stock-news.laohu8.com/highlight/detail?id=2600031055","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600031055?lang=en_us&edition=fundamental","pubTime":"2026-01-02 06:38","pubTimestamp":1767307110,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260101:nTUE9FP4WP:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","BK4139","MESO","BK7501","MSB.AU"],"gpt_icon":0},{"id":"2600031053","title":"Mesoblast Ltd-Mesoblast Announces Changes to Board of Director Roles","url":"https://stock-news.laohu8.com/highlight/detail?id=2600031053","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600031053?lang=en_us&edition=fundamental","pubTime":"2026-01-02 06:38","pubTimestamp":1767307110,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260101:nTUE9FP4WP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","BK7508","BK7067","MSB.AU"],"gpt_icon":0},{"id":"2595768897","title":"Mesoblast Ltd Files for Offering of Upto $250 Mln Ads Representing Ordinary Shares - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2595768897","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595768897?lang=en_us&edition=fundamental","pubTime":"2025-12-31 19:30","pubTimestamp":1767180612,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nFWN3Y103D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MESO","BK7508","BK7501","BK4139","MSB.AU","BK7067"],"gpt_icon":0},{"id":"2595769466","title":"Mesoblast to Release 10.2 Million Shares From Voluntary Escrow","url":"https://stock-news.laohu8.com/highlight/detail?id=2595769466","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595769466?lang=en_us&edition=fundamental","pubTime":"2025-12-30 14:06","pubTimestamp":1767074805,"startTime":"0","endTime":"0","summary":"Mesoblast (ASX:MSB) said that 10.2 million of its shares will be released from voluntary escrow on Jan. 8, 2026, in accordance with the Australian Securities Exchange's listing rule 3.10A, according to a Tuesday Australian bourse filing.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XAO.AU","BK7508","BK7501","XKO.AU","BK4139","MSB.AU","XJO.AU","BK7067","MESO"],"gpt_icon":0},{"id":"2595759386","title":"Press Release: Mesoblast Retires Senior Debt with Non-Dilutive, Lower Cost, Five-Year Credit Line","url":"https://stock-news.laohu8.com/highlight/detail?id=2595759386","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595759386?lang=en_us&edition=fundamental","pubTime":"2025-12-30 07:57","pubTimestamp":1767052620,"startTime":"0","endTime":"0","summary":"Mesoblast has option to draw down up to US$125 million by June 30, 2026. New facility does not encumber any of Mesoblast's material assets or intellectual property. The new credit-line has a fixed interest rate of 8.00% per annum, a substantial reduction from Mesoblast's current debt facilities, with a five-year interest only period. The initial US$75 million drawn is unsecured until the remainder of the NovaQuest debt is repaid, no later than July 8, 2026, after which the entire new facility  will be secured solely with the Temcell royalty.Mesoblast's Ryoncil  for the treatment of steroid-refractory acute graft versus host disease  in pediatric patients 2 months and older is the first FDA-approved mesenchymal stromal cell  therapy. Please see the full Prescribing Information at www.ryo","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MESO","MSB.AU","BK7067","R","BK4150","BK4022","BK7508","BK4006","MSC","BK7501","BK4575","BK4232","MSB"],"gpt_icon":0},{"id":"2595756078","title":"Mesoblast Repays Existing Senior Loans From Shareholder's New Five-Year Facility; Shares Rise 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595756078","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595756078?lang=en_us&edition=fundamental","pubTime":"2025-12-30 07:44","pubTimestamp":1767051874,"startTime":"0","endTime":"0","summary":"Mesoblast  repaid its existing senior secured loan from Oaktree Capital Management in full and its royalty facility from NovaQuest Capital Management in part, according to a Tuesday filing with the Australian bourse.The repayment followed a $75 million withdrawal from a new five-year facility of up to $125 million provided by a shareholder, carrying a fixed interest rate of 8% per annum, the filing said.The company has an option to withdraw up to $50 million until June 30, 2026, the filing said.The shareholder will receive warrants to purchase about 323,00 American Depositary Shares  at $21.51 per ADS, the filing added.The facility can be repaid without incurring early payment or make-whole fees, the company said.Shares of the company rose 3% in recent Tuesday trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7016","ADS.AU","MESO","MSB.AU","BK7508","BK7501","BK7067","BK4139"],"gpt_icon":0},{"id":"2595771512","title":"ASX Biggest Losers","url":"https://stock-news.laohu8.com/highlight/detail?id=2595771512","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595771512?lang=en_us&edition=fundamental","pubTime":"2025-12-29 09:07","pubTimestamp":1766970431,"startTime":"0","endTime":"0","summary":"Here are the 10 ASX-listed companies with the biggest losses on Monday.DroneShield : 5%, AU$3.15Netwealth Group : 5%, AU$25.49Neuren Pharmaceuticals : 3%, AU$19.17West African Resources : 2%, AU$3.0750Capricorn Metals : 2%, AU$14.39Austal : 2%, AU$6.69Nick Scali : -2%, AU$23.57HUB24 : 2%, AU$95.85Pinnacle Investment Management Group : 2%, AU$17.07Mesoblast  : 1%, AU$2.8600","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","BK7104","DRO.AU","BK7506","BK7054","BK7107","NEU.AU","WAF.AU","BK7067","NWL.AU","CMM.AU","MSB.AU","PNI.AU","HUB.AU","BK7115","BK7508","BK7062","BK7501","NCK.AU","ASB.AU"],"gpt_icon":0},{"id":"2592791957","title":"Has Mesoblast’s Surging Share Price Left Its Future Growth Prospects Underappreciated?","url":"https://stock-news.laohu8.com/highlight/detail?id=2592791957","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592791957?lang=en_us&edition=fundamental","pubTime":"2025-12-17 09:16","pubTimestamp":1765934210,"startTime":"0","endTime":"0","summary":"If you are wondering whether Mesoblast is a hidden bargain or a value trap at its current share price, you are not alone. This breakdown aims to unpack that question.\nThe stock has been choppy in the short term, down 1.8% over the last week. That comes after a 24.8% jump over the past month and a 42.8% gain over the last year, all against a still negative year to date return of 17.3% and a 215.8% rise over three years.\nRecent moves have been driven less by day to day noise and more by...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/has-mesoblasts-surging-share-price-left-its-future-growth-pr","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/has-mesoblasts-surging-share-price-left-its-future-growth-pr","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7508","BK7501","BK4139","DCF","BK7067","MESO","MSB.AU"],"gpt_icon":0},{"id":"2591829670","title":"Aspire Announces Major Australia, EU and US Regulatory Milestones, Marking a New Chapter in Its Global Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2591829670","media":"prnewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591829670?lang=en_us&edition=fundamental","pubTime":"2025-12-16 12:23","pubTimestamp":1765858980,"startTime":"0","endTime":"0","summary":"SINGAPORE, Dec. 16, 2025 /PRNewswire/ -- Aspire, the Singapore-headquartered fintech, today announced a series of regulatory milestones marking a major step in its global expansion. Over the past year alone, the company has secured eight licenses and registrations, strengthening its footprint across Australia, Europe and the United States and laying the foundation for its next phase of growth in some of the world's most important financial hubs.In Australia, Aspire has been granted a full Australian Financial Services License . This strengthens its presence in Asia Pacific and enables the company to deliver its financial stack to Australian businesses directly. With the new license, Aspire will bring its full financial stack, including multicurrency accounts, payments, cards and spend, to Australian companies that increasingly expect a modern, integrated finance platform.2025 has been a defining year for Aspire, from securing major licenses to deepening its footprint in Asia. The compa","market":"fut","thumbnail":"https://mma.prnewswire.com/media/2752414/Aspire_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2752414/Aspire_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/aspire-announces-major-australia-eu-and-us-regulatory-milestones-marking-a-new-chapter-in-its-global-expansion-302642993.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XJO.AU","LU0545039389.USD","BK4585","SEC.AU","BK7508","LU0661504455.SGD","BK4588","EMI","BK7501","XAO.AU","LU0553294199.USD","LU0949170772.SGD","BK4208","LU1003077747.HKD","LU2346227817.USD","BK7067","BK4006","XKO.AU","MSB","LU0738911758.USD","LU1894683348.USD","MSB.AU","LU1894683264.USD","LU2637428348.USD","BK4156","LU2500361329.USD","CMS"],"gpt_icon":0},{"id":"2590526802","title":"Mesoblast Says Drug Candidate for Treatment of Severe Acute Graft Versus Host Disease Shows Superior Outcomes Than Ruxolitinib","url":"https://stock-news.laohu8.com/highlight/detail?id=2590526802","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590526802?lang=en_us&edition=fundamental","pubTime":"2025-12-12 10:06","pubTimestamp":1765505219,"startTime":"0","endTime":"0","summary":"Mesoblast  said drug candidate Ryoncil  showed superior outcomes in complete and overall remission in a comparison study with ruxolitinib for treatment of steroid-refractory acute graft versus host disease, following an independent, peer-reviewed comparative study, according to a Friday filing with the Australian bourse.Shares of the company rose 2% in recent Friday trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7501","BK4139","MSB.AU","BK7508","MESO","BK4585","BK4181","SPN","BK4588","BK4218","HST","BK7067"],"gpt_icon":0},{"id":"2590473445","title":"Mesoblast Study Finds Remestemcel-L Outperforms Ruxolitinib in Treating Steroid-Refractory aGvHD","url":"https://stock-news.laohu8.com/highlight/detail?id=2590473445","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590473445?lang=en_us&edition=fundamental","pubTime":"2025-12-12 07:22","pubTimestamp":1765495366,"startTime":"0","endTime":"0","summary":"Mesoblast Limited announced the results of an independent, peer-reviewed comparative analysis of remestemcel-L and ruxolitinib for the treatment of steroid-refractory acute graft versus host disease . The findings, presented at the 67th American Society of Hematology  Annual Meeting, concluded that remestemcel-L demonstrated superior outcomes in complete and overall remission compared to ruxolitinib. The meta-analysis included 2,732 patients across 11 studies, with 644 patients receiving remestemcel-L and 1,349 receiving ruxolitinib. Both therapies improved quality of life in SR-aGvHD patients, but the analysis noted differences in hematology, cardiac, and hepatic adverse events. Ryoncil, the commercial name for remestemcel-L, is the first mesenchymal stromal cell product approved by the U.S. FDA for any indication and is currently the only product approved for children under age 12 with SR-aGvHD.Disclaimer: This news brief was created by Public Technologies  using generative artificia","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDLHttsR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK7067","LU2210150020.SGD","SG9999014021.USD","SG9999014039.USD","BK4112","MSB.AU","LU0314104364.USD","IE00BKPKM429.USD","IE00BGHQF748.EUR","SG9999014013.SGD","IE00B3QW5Z07.USD","BK7508","IE00B64PRP62.GBP","LU2095319765.USD","BK4588","SG9999014005.SGD","NDAQ","BK4585","LU2210149790.SGD"],"gpt_icon":0},{"id":"2590547349","title":"Independent Study Presented at American Society of Hematology (Ash) Annual Meeting Concludes Remestemcel-L Superior to Ruxolitinib in Clinical Outcomes as Treatment for SR-Agvhd","url":"https://stock-news.laohu8.com/highlight/detail?id=2590547349","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590547349?lang=en_us&edition=fundamental","pubTime":"2025-12-12 07:22","pubTimestamp":1765495347,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nTUA9T2Z43:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7501","BK7508","MSB.AU"],"gpt_icon":0},{"id":"2590541654","title":"Is Mesoblast (ASX:MSB) Using High-Profile Conferences To Recast Its Core Investment Narrative?","url":"https://stock-news.laohu8.com/highlight/detail?id=2590541654","media":"Simply Wall St.","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590541654?lang=en_us&edition=fundamental","pubTime":"2025-12-11 22:33","pubTimestamp":1765463582,"startTime":"0","endTime":"0","summary":"Mesoblast Limited recently presented at the Piper Sandler 37th Annual Healthcare Conference in New York, led by Founder and CEO Silviu Itescu.\nThe CEO’s direct participation in this high-profile healthcare forum positioned Mesoblast to highlight its scientific direction, clinical priorities, and broader corporate story to an influential audience.\nWe’ll now examine how Mesoblast’s high-profile conference appearance with direct CEO participation may influence the company’s broader investment...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/is-mesoblast-asxmsb-using-high-profile-conferences-to-recast","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/is-mesoblast-asxmsb-using-high-profile-conferences-to-recast","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7501","MSB.AU","BK7508","BK7067","BK4006","MSB"],"gpt_icon":0},{"id":"2590574534","title":"Mesoblast (ASX:MSB) Valuation Check as Investors Eye Piper Sandler Healthcare Conference Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2590574534","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590574534?lang=en_us&edition=fundamental","pubTime":"2025-12-10 21:27","pubTimestamp":1765373230,"startTime":"0","endTime":"0","summary":"Mesoblast (ASX:MSB) steps into the spotlight this week as CEO Silviu Itescu presents at the Piper Sandler 37th Annual Healthcare Conference, and traders are watching for fresh color on strategy and late stage trials.\nSee our latest analysis for Mesoblast.\nThat anticipation has arrived on the back of a strong near term rebound, with a 1 month share price return of 27.03 percent and a 1 year total shareholder return of 65.88 percent, even though the year to date share price return remains...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-valuation-check-as-investors-eye-piper-sand","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-valuation-check-as-investors-eye-piper-sand","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["XLV","BK4585","BK4006","BK7501","BK4581","BK7067","BK4137","HCSG","BK7508","MSB","BK4588","LABU","XBI","MSB.AU","LU0029874061.USD","ISBC","BK4211","LU0128526141.USD","DCF"],"gpt_icon":0},{"id":"2590041013","title":"Matrixport Appoints Dominik Oggenfuss as Chief Executive Officer of Matrixport Asset Management AG","url":"https://stock-news.laohu8.com/highlight/detail?id=2590041013","media":"prnewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590041013?lang=en_us&edition=fundamental","pubTime":"2025-12-10 16:00","pubTimestamp":1765353600,"startTime":"0","endTime":"0","summary":"Seasoned finance leader to drive company's next phase of growth and innovation. ZURICH, Dec. 10, 2025 /PRNewswire/ -- Matrixport Groupis pleased to announce the appointment of Dominik Oggenfuss as Chief Executive Officer of Matrixport Asset Management AG, effective today.\"With our Swiss asset management platform in place, Matrixport Asset Management is entering its next phase focused on scaling an institution-grade business across Europe. Dominik's appointment reflects our priorities in strengthening investment capabilities and building a long-term presence in key European markets.\" said John Ge, CEO of Matrixport Group.\"I am honored to join Matrixport Asset Management AG as CEO and I look forward to working with the talented team. Being part of Matrixport Group, a global digital asset player in Asia, I am convinced we can deliver innovative investment solutions, strengthen client relationships, and expand Matrixport Group's presence in both traditional and digital asset markets in Swi","market":"hk","thumbnail":"https://mma.prnewswire.com/media/2529911/Matrixport_2024_2025_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2529911/Matrixport_2024_2025_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/matrixport-appoints-dominik-oggenfuss-as-chief-executive-officer-of-matrixport-asset-management-ag-302637423.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","MSB","BK4006","AG","MSB.AU","BK4210","BK7501","BK7067"],"gpt_icon":0},{"id":"2588020693","title":"Mesoblast Participation at Piper Sandler Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2588020693","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588020693?lang=en_us&edition=fundamental","pubTime":"2025-12-04 07:10","pubTimestamp":1764803406,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nTUAB5NC3F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PIPR","BK7067","BK7501","BK4127","BK7508","MSB.AU"],"gpt_icon":0},{"id":"2587754974","title":"Mesoblast (ASX:MSB) Is Up 17.3% After Lifting Revenue Guidance and Announcing NIH Trial Collaboration Has The Bull Case Changed?","url":"https://stock-news.laohu8.com/highlight/detail?id=2587754974","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587754974?lang=en_us&edition=fundamental","pubTime":"2025-11-29 09:23","pubTimestamp":1764379395,"startTime":"0","endTime":"0","summary":"Mesoblast Limited recently released updated revenue guidance, projecting gross revenue of over US$30.0 million from Ryoncil® sales for the quarter ending December 31, 2025, and announced a collaborative pivotal trial with the NIH-funded Blood and Marrow Transplant Clinical Trials Network for Ryoncil® in adults with severe acute graft versus host disease.\nThis combination of higher sales forecasts and expanded clinical research signals an important step as Mesoblast seeks to broaden both its...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-is-up-173-after-lifting-revenue-guidance-an","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-is-up-173-after-lifting-revenue-guidance-an","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MSB","MSB.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":8,"pageCount":5,"totalSize":146,"code":"91000000","status":"200"}]}}